SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny as investors grapple with a sustained multi-year decline and ongoing concerns over brand relevance, tariff-related margin pressures, and fierce competition from emerging industry peers. While some community members are betting on a turnaround fueled by long-term dividend yield and potential tariff-related financial tailwinds, sentiment remains polarized between those aggressively shorting the stock at decade lows and contrarian investors seeking an entry point for a bottoming play.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as a major federal trial begins, with 29 state attorneys general alleging that its social media platforms are designed to cause addiction and harm to young users. The community is sharply divided, with some investors fearing the legal and financial liability could weigh on the stock, while others view the pullback as a buying opportunity in a company still bolstered by robust ad revenue and aggressive AI infrastructure growth.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in investor interest driven by strong institutional accumulation and growing confidence in its upcoming Biologics License Application for aglatimagene. Community discussion is focused on the company's progress toward commercialization, favorable clinical data, and speculation regarding potential long-term value in the prostate cancer market.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently facing intense selling pressure as investors struggle with a persistent bond sell-off, driven by concerns over record national debt levels and ongoing uncertainty regarding the Fed's ability to control long-term yields. While the community remains deeply polarized between those calling for a structural collapse toward multi-decade lows and contrarian bulls attempting to capture a technical bottom, the prevailing sentiment is one of extreme caution amid high energy prices and geopolitical instability.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the community debate the company's future amid intensifying volatility and polarized political discourse surrounding its namesake. Discussions are dominated by speculation over the firm's business prospects and broader economic concerns, while retail participants actively trade heated views on current events and market sentiment.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is currently experiencing heightened volatility as investors weigh strong earnings growth against broader sector-wide selling in AI infrastructure and connectivity names. Despite the price correction, the community remains actively divided, with many traders viewing the pullback as a buying opportunity while others express concern over stretched valuations and a shifting market sentiment regarding AI capital expenditure cycles.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors digest a strong earnings report that highlighted record revenue and expanding commercial reach, fueling expectations for an upcoming upward guidance revision. The community is actively debating the stock's potential for a short squeeze and its long-term valuation prospects as they anticipate key data readouts for lung cancer indications later this year.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant volatility and trading volume as investors weigh record backlog growth against recent earnings results. Community sentiment remains deeply polarized, with bullish traders highlighting the company's long-term defense and lunar infrastructure contracts, while bears focus on dilution concerns and recent downward price movements.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is surging as investors shift their focus from its legacy video platform to the rapid expansion of its Quake AI infrastructure, fueled by the completed Northern Data acquisition and significant cloud spending commitments from Tether. The community is actively discussing a potential short squeeze, citing record-high short interest and the strategic value of Rumble's growing GPU capacity and energized data center pipeline.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is currently facing significant downward pressure as investors react to ongoing inventory challenges, shifting electrification strategies, and analyst downgrades. Community discussion is sharply divided between those calling for a turnaround based on strong cash reserves and value-oriented metrics, and those expressing frustration over management performance and the company's recent stock price decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics is trending due to a regulatory pivot where the FDA expressed willingness to review a major BLA amendment containing 24-month clinical data, potentially leading to a PDUFA date extension. The community is heavily focused on the high short interest and the prospect of a massive short squeeze as analysts significantly raise price targets following this path to a refined upper-limb indication.

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom

Capricor shares are rising after the FDA signaled flexibility to review 24-month HOPE-3 data in an amended BLA supporting a narrower upper-limb indication, with the agency set to extend the Aug. 22 PDUFA date. Goldman Sachs also raised its stake by 73% to 1.58 million shares worth $38 million, adding to bullish sentiment around the regulatory path.

Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom 

Equity

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm

CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm CAPR Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CAPR Investors with Losses to Contact the Firm PR Newswire RADNOR, Pa., Aug. 16, 2026 Did you buy CAPR securities...

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman PR Newswire SAN FRANCISCO, Aug. 14, 2026...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (NASDAQ: CAPR) on behalf of those who purchased or acquired...

The Money Machine Is Back, as Biotech, AI, and Tech Names Explode

Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Wetour Robotics (NASDAQ:WETO), Onfolio Holdings (NASDAQ:ONFO), and Creative Global Technology Holdings (NASDAQ: CGTL) are much more structure-sensitive.

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.read more...

CAPR’s FDA Showdown Is Here: The Advisory Committee Said No, But the Real Decision Hasn’t Happened Yet

The market may be treating Capricor Therapeutics (NASDAQ:CAPR) as if the July 29 FDA advisory committee vote delivered a knockout blow, but it didn't. It delivered a major setback, but the actual regulatory story appears to be considerably more complicated and, with the Deramiocel BLA still under active FDA review and a PDUFA action date of August 22, the most important decision has yet to be made.

CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path

Cantor Fitzgerald upgraded Capricor to ‘Overweight’ from ‘Neutral’ and raised its price target to $28 from $3.50, just weeks after the firm slashed its price target to $3.50 from $62.


S&P 500, Nasdaq Futures Pause Near Record Highs: Why SPCX, AMAT, SNDK, CSCO, CAPR, SLS, ONDS Stocks Are In Focus

Retail sentiment on Stocktwits remained improved to ‘bullish’ on SPY and remained ‘bearish’ on QQQ.


Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

High short interest and rising borrow rates have traders anticipating a violent parabolic move as sellers scramble to cover positions.

Goldman Sachs recently increased its stake significantly, sparking intense debate among retail investors about long-term potential versus trap risks.

Market attention is hyper-focused on the anticipated BLA amendment and a potential new PDUFA date to break the regulatory deadlock.

Frantic debates are breaking out regarding the legitimacy of overnight trading movements, with skeptics calling them orchestrated algo traps.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAPRCapricor Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest CAPR News